Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients

Lupus

Volumn 12, Issue 10, 2003, Pages 788-794

  Soares, Márcio ^a,b,c   Reis, L ^a   Papi, J A S ^a   Cardoso, C R L ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c NONE   (Brazil)

Author keywords

Antiphospholipid syndrome; Arterial hypertension; Damage index; Morbidity; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; STEROID;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; BRAZIL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; EYE DISEASE; FEMALE; HUMAN; HYPERTENSION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BRAZIL; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 0142023730     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu447xx     Document Type: Article

References (38)

1. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology 2000; 39: 238-244.
2. Gladman DD. Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1994; 6: 487-492.
3. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
4. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.
5. Gorgos L, Goldman D, Petri M. The ACR/SLICC Damage Index in systemic lupus erythematosus (SLE). Arthritis Rheum 1993; 36(Suppl.): S68 (abstract 180).
6. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 309-313.
7. Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998; 25: 654-659.
8. Zonana-Nacach A, Camargo Coronel A, Yáñez P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 119-123.
9. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
10. Gilboe I-M, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28: 266-274.
11. Maddison P, Farewell V, Isenberg D et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 2002; 29: 913-917.
12. Nived O, Jönsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398-1400.
13. Fortin PR, Abrahamowicz M, Neville C et al. Impact of disease activity and cumulative damage on the health oflupus patients. Lupus 1998; 7: 101-107.
14. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-254.
15. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999; 8: 632-637.
16. Tan EN, Cohen AS, Fries JF et al. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
17. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
19. Rivest C, Lew RA, Welsing PMJ et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol 2000; 27: 680-684.
20. Alarcón GS, McGwin Jr G, Bastian HM et al. Systemic lupus erythematosus in three ethnic groups: VIII. Predictors ofearly mortality in the LUMINA cohort. Arthritis Care Res 2001; 45: 191-202.
21. Bezerra MC, Saraiva MC, Borba EF, Gonçalves CR, Bonfá E. Dano precoce no lupus eritematoso sistêmico-Associado à atividade de doença ou à terapêutica? Rev Bras Reumatol 2002; 42(Suppl 1): S103 (abstract 239).
22. Santana MVS, Minami CSH, Ramalho RMM, Szajubok JCM, Araújo NC, Chahade WH, Aspectos clínicos de pacientes com lúpicos com duração de doença maior que dez anos. Avaliaçã o preliminar. Rev Bras Reumatol 2002; 42(Suppl 1): S87 (abstract 175).
23. Sella EMC, Silva EA, Sato EI. Avaliação do índice de danos permanentes pelo Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for Systemic Lupus Erythematosus em 112 pacientes. Rev Bras Reumatol 2002; 42(Suppl 1): S89 (abstract 185).
24. Thumboo J, Fong K-Y, Chan S-P et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000; 27: 1414-1420.
25. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus. Cumulative disease activity and medication use predicts disease damage. Arthritis Rheum 2002; 46: 436-444.
26. Watson R. Cutaneous lesions in systemic lupus erythematosus. Med Clin North Am 1989; 73: 1091-1111.
27. Johnson AE, Cavalcanti FS, Gordon C et al. Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus 1994; 3: 501-550.
28. Alarcón GS, McGwin Jr G, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797-2806.
29. Karlson EW, Daltroy LH, Lew RA et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 47-56.
30. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic erythematosus lupus international comparison. J Rheumatol 2000; 27: 373-376.
31. Amigo M-C. Prognosis in antiphospholipid syndrome. Rheum Dis Clin North Am 2001; 27: 661-669.
32. Ganezarezyk L, Urowitz M, Gladman DD. Latent lupus. JRheumatol 1989; 16: 475-478.
33. Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Int Med 1989; 149: 2473-2476.
34. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: Strengths, weakness, and opportunities for improvement. Lupus 1999; 8: 586-595.
35. Petri M. Hydroxychloroquine prevents later damage in SLE. Arthritis Rheum 2001; 44(Suppl 9): S247 (abstract 1363).
36. Molad Y, Gorshtein A, Wysenbeek AJ et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002; 11: 356-361.
37. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 257-278.
38. Hallegua DS, Wallace DJ. How accelerated atherosclerosis in SLE has changed our management of the disorder. Lupus 2000; 9: 228-231.